Intratumoral Cancer Therapies epidemiology report 2030 gives a thorough understanding of the Intratumoral Cancer Therapies by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

Intratumoral Cancer Therapies Epidemiology Insight

DelveInsight&rsquo;s &lsquo;Intratumoral Cancer Therapies- Epidemiology Forecast to 2030&rsquo; report delivers an in-depth understanding of the Intratumoral Cancer Therapies across the several selected cancer types, historical and forecasted Intratumoral Cancer Therapies epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

<h2>Geography Covered</h2>

<ul>
	<li>The United States</li>
	<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li>
	<li>Japan</li>
</ul>

Study Period: 2018&ndash;2030

<h2>Intratumoral Cancer Therapies Understanding</h2>

Over the years, the research and development in cancer have drastically increased, and patients now have several treatment options, which mainly includes chemotherapy, hormone therapy, immunotherapy, gene therapy, radiotherapy, stem cell transplant, surgery, and targeted therapy. However, there is still a segment of the cancer patient population who cannot achieve any benefit or improvement from these therapeutic options. These patients face several challenges, including the development of resistance against these therapies. While the research and development for developing treatment options to mitigate prevailing limitations are still undergoing, researchers and industries have developed a keen interest in Intratumoral therapies. Intratumoral (intralesional) administration of immunotherapeutics is a promising way to target local tumor immunity barriers directly. Even though intratumoral therapy most often refers to direct injection into the tumors, it can also refer to any therapy provided in close anatomical proximity to a tumor with the goal of direct uptake by tumors. There are different categories of intratumoral therapies: cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules.

&nbsp;

Currently, only three intratumoral therapies are approved; Imlygic (Talimogene laherparepvec/T-VEC; Amgen), the first oncolytic virus that was approved by the US FDA for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery in 2015. Later, in April 2020, the EU granted approval (CE mark) to Hensify (NBTXR3; Nanobiotix) for the treatment of locally advanced soft tissue sarcoma (STS), however it is not launched yet. Recently, in June 2021, Delytact (teserpaturev/G47∆; Daiichi Sankyo) received conditional and time-limited approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with malignant glioma. The emerging pipeline is majorly focused on the treatment of melanoma, head and neck cancer, Nonmelanoma skin cancer, along with some other cancers and expectations are high from Intratumoral Cancer Therapies.

<h2>Epidemiology Perspective by DelveInsight</h2>

The Intratumoral Cancer Therapies epidemiology division provides the insights about historical and current indication wise eligible patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

&nbsp;

Key Findings 

The disease epidemiology covered in the report provides historical as well as forecasted Intratumoral Cancer Therapies epidemiology [segmented as Total Incident cases of selected cancer types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Colorectal Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma), Target patient Pool of Intratumoral therapies by Cancer Types and Treated cases by Cancer Types] scenario of Intratumoral Cancer Therapies in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.

<h2>Country Wise- Intratumoral Cancer Therapies Epidemiology</h2>

<ul>
	<li>Among selected nine major indications for the Intratumoral therapies, Nonmelanoma skin cancer (NMSC) contributed to the highest number of cases in the 7MM. The total number of NMSC in the 7MM was 774,926 in 2020. The United States, with 524,737 NMSC incident cases, had the highest number of NMSC incident cases among the seven major markets.</li>
	<li>In 2020, the total Indication-wise eligible cases were 736,184 cases in the 7MM, whereas, Japan accounted for 126,718 Indication-wise eligible cases in the same year which are projected to increase during the forecast period, i.e., 2021&ndash;2030.</li>
	<li>In the 7MM, the total treated cases of all selected cancer types in neoadjuvant/adjuvant setting and first-line were 1,065,771, and 736,184 in 2020, which are expected to grow during the forecast period, i.e., 2021&ndash;2030.</li>
</ul>

<h2>Scope of the Report</h2>

<ul>
	<li>The Intratumoral Cancer Therapies report covers a detailed overview of the development of Intratumoral Cancer Therapies across the several selected cancer types, explaining its various classes, benefits, and challenges for future.</li>
	<li>The Intratumoral Cancer Therapies Report and Model provide an overview of the risk factors and global trends of Intratumoral Cancer Therapies in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)</li>
	<li>The report provides insight about the historical and forecasted patient pool of Intratumoral Cancer Therapies in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.</li>
	<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.</li>
	<li>The report assesses the selected cancer types risk and burden and highlights the unmet needs of Intratumoral Cancer Therapies.</li>
	<li>The report provides the segmentation of the Intratumoral Cancer Therapies epidemiology by total Incident cases of selected cancer types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Colorectal Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma) in the 7MM.</li>
	<li>The report provides the segmentation of the Intratumoral Cancer Therapies epidemiology by target patient Pool of Intratumoral therapies by Cancer Types in the 7MM.</li>
	<li>The report provides the segmentation of the Intratumoral Cancer Therapies epidemiology by Treated cases by Cancer Types in the 7MM.</li>
</ul>

<h2>Report Highlights</h2>

<ul>
	<li>10-Year Forecast of selected cancer types for Intratumoral Cancer Therapies</li>
	<li>Target/Eligible patient Pool for Intratumoral therapies by Cancer Types</li>
	<li>Total Treated cases by Cancer Types</li>
	<li>7MM Coverage</li>
</ul>

<h2>KOL-Views</h2>

We interview, KOL&rsquo;s and SME&#39;s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

<h2>Key Questions Answered</h2>

<ul>
	<li>What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Intratumoral Cancer Therapies?</li>
	<li>What are the key findings pertaining to the Intratumoral Cancer Therapies epidemiology across the 7MM and which country will have the highest number of incident cases of selected cancer types for Intratumoral Cancer Therapies the study period (2018&ndash;2030)?</li>
	<li>What would be the total number of patients of Intratumoral Cancer Therapies across the 7MM during the study period (2018&ndash;2030)?</li>
	<li>Among the EU5 countries, which country will have the highest incident cases of selected cancer types for Intratumoral Cancer Therapies during the study period (2018&ndash;2030)?</li>
	<li>At what CAGR the patient population is expected to grow in the 7MM during the study period (2018&ndash;2030)?</li>
	<li>What are the various recent and upcoming events which are expected to improve the uptake of Intratumoral Cancer Therapies?</li>
</ul>

<h2>Reasons to buy</h2>

The Intratumoral Cancer Therapies Epidemiology report will allow the user to -

<ul>
	<li>Develop business strategies by understanding the trends shaping and driving the global Intratumoral Cancer Therapies market</li>
	<li>Quantify patient populations in the global Intratumoral Cancer Therapies market to improve product design, pricing, and launch plans</li>
	<li>Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Intratumoral Cancer Therapies therapeutics in each of the markets covered</li>
	<li>The Intratumoral Cancer Therapies epidemiology report and model were written and developed by Masters and PhD level epidemiologists</li>
	<li>The Intratumoral Cancer Therapies Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources</li>
</ul>

<h2>Key Assessments</h2>

<ul>
	<li>Patient Segmentation</li>
	<li>Selected Disease Risk and Burden</li>
	<li>Factors driving growth in a specific disease patient population</li>
</ul>

1. Key Insights

2. Executive Summary of Intratumoral cancer therapy

2.1. Key Events

3. Epidemiology Forecast Flow

4. Background and Overview

4.1. Introduction

4.2. Cancer Therapy

4.3. Intratumoral Therapies

4.4. History of Intratumoral Therapies

4.5. Mechanism of Intratumoral Therapies

4.6. Principles of Intratumoral Immunotherapy

4.6.1. In Situ Priming of Antitumor Immunity

4.6.2. Use the Tumor as its Own Vaccine

4.6.3. Avoid Systemic Toxicities

4.7. Tumor Properties to Consider for Intratumoral Therapies

4.7.1. Tumor Microenvironment

4.7.2. Intratumoral Transport

4.8. Categories of Intratumoral Therapies

4.8.1. Pathogen-associated Molecular Patterns (PAMPs)

4.8.2. Cytokines

4.8.3. Oncolytic Viruses

4.8.4. Cancer Gene Therapy

4.8.5. Monoclonal Antibodies

4.8.6. Small Molecules

4.9. Advantages of Intratumoral Therapies

4.10. Limitations of Intratumoral Therapies

4.10.1. Emerging Therapies and Future Directions

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Assumptions and Rationale

5.3. Epidemiology Scenario

5.3.1. Total Incident cases of selected cancer types across the 7MM

5.3.2. Target Patient Pool of Intratumoral therapies by Cancer Types across the 7MM

5.3.3. Treated cases by Cancer Types across the 7MM

6. Appendix

6.1. Bibliography

6.2. Report Methodology

7. DelveInsight Capabilities

8. Disclaimer

9. About DelveInsight

Intratumoral Cancer Therapies - Epidemiology Forecast to 2030

DelveInsight's Intratumoral Cancer Therapies - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology..